NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences

Press Releases

NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences

WALTHAM, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the 10th Annual Biotech Showcase 2018 Conference at the Hilton San Francisco Union Square on Monday, January 8 at 11:00 a.m. (Pacific). A live webcast will be available on the investor relations page at and will be archived after the event.  Dr. Gozani will also present at the Digital Medicine & Medtech Showcase on Tuesday, January 9 at 1:00 p.m. (Pacific) which will not be webcast. Both talks will highlight the Company's Quell® Wearable Pain Relief Technology™ and provide an update on the Company’s business activities.  

About Quell

Quell is an advanced, wearable technology for treating chronic pain.  It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription.  Quell users can personalize and manage therapy discreetly via the Quell app.  Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait.  Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases.  Quell is available online and through select retailers. Visit for more information.

About NeuroMetrix

NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital health to address chronic health conditions including chronic pain, diabetes, and sleep disorders. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain.  The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer

Source: NeuroMetrix, Inc.

Primary Logo


Source: NeuroMetrix, Inc.